Please use this identifier to cite or link to this item:
Title: Modulation of gold(III) porphyrin 1a-induced apoptosis by mitogen-activated protein kinase signaling pathways
Authors: Wang, Y;He, QY;Che, CM;Tsao, SW;Sun, RWY;Chiu, JF
subject: Apoptosis;Gold(III) compound;MAPK;Mitochondria;Proteomics;Tyrosine phosphorylation
Year: 2008
Publisher: Elsevier Inc. The Journal's web site is located at
United States
Description: Gold(III) porphyrin 1a is a novel gold(III) complex with selective anticancer effect in a number of human carcinoma cell lines. We have previously shown that gold(III) porphyrin 1a mediated mitochondrial transmembrane potential (ΔΨm) depletion, leading to cytochrome c release, nucleus translocation of apoptosis-inducing factor (AIF), and generation of reactive oxygen species (ROS). The current study addressed gold(III) porphyrin 1a-induced phosphoproteome alterations and modulation of cell death by the mitogen-activated protein kinase (MAPK) family proteins. ERK and p38MAPK were transiently activated upon gold(III) porphyrin 1a treatment. Inhibition of p38MAPK phosphorylation rescued gold(III) porphyrin 1a-induced cell death upstream of caspase activation. Attenuation of ΔΨm was the primary effect of gold(III) porphyrin 1a leading to p38MAPK phosphorylation. Further functional proteomic study suggested that differential regulation of phosphotyrosine proteins were related to p38MAPK activation in gold(III) porphyrin 1a-induced signal transduction cascade. In summary, p38MAPK modulated gold(III) porphyrin 1a-induced cell death downstream of mitochondria, and phosphorylation of multiple proteins also involved in this process. These results suggested that gold(III) porphyrin 1a is a promising anticancer agent directed toward the mitochondria. © 2007 Elsevier Inc. All rights reserved.
Standard no: Biochemical Pharmacology, 2008, v. 75 n. 6, p. 1282-1291
Appears in Collections:Department of Anatomy

Files in This Item:
Click on the URI links for accessing contents.

Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.